Summary
Cannot be evaluated against FDA-approved prescribing information because the prompt did not provide the actual AI-generated response to audit (only a list of candidate statements) and provided FDA label excerpts only cover warnings (Sections 5.1–5.5), not indications, dosing/administration, contraindications, interactions, adverse reactions, or storage/handling. Therefore, most claims are unassessable for support/contradiction/omission.
Category Scores
Accurate Statements
Unsupported Statements
Cefixime oral suspension is used to treat bacterial infections.
Not supported by the provided FDA labeling excerpts (only Sections 5.1–5.5 warnings were provided; no indication section text was provided).
Cefixime oral suspension is effective against bacterial infections affecting the urinary tract/ears/nose/throat/lungs.
Not supported by the provided FDA labeling excerpts; indication/spectrum details were not provided.
Cefixime oral suspension is commonly prescribed for bronchitis/pneumonia/otitis media/pharyngitis/uncomplicated urinary tract infections.
Not supported by the provided FDA labeling excerpts; prescriptive/common-use assertions and approved indications were not provided.
Cefixime works by inhibiting the synthesis of bacterial cell walls.
Mechanism-of-action details were not provided in the supplied label excerpts.
Cefixime leads to bacterial death.
Not supported by the provided FDA labeling excerpts.
Cefixime oral suspension typically requires reconstitution with water before administration.
Storage/handling/administration instructions were not provided in the supplied FDA label excerpts.
After reconstitution, cefixime oral suspension should be stored at room temperature.
Storage instructions were not provided in the supplied FDA label excerpts.
After reconstitution, cefixime oral suspension should be used within a specified period, often 7 to 14 days.
Storage/usable-period instructions were not provided in the supplied FDA label excerpts; specific time window not verifiable.
Cefixime oral suspension should be shaken well before each dose to ensure uniform distribution of the medication.
Administration instructions were not provided in the supplied FDA label excerpts.
Common side effects may include diarrhea/nausea/vomiting/abdominal pain.
Adverse reaction frequency/typical side effects were not provided in the supplied FDA label excerpts.
Allergic reactions such as rash or itching can occur with cefixime oral suspension.
The supplied label excerpts mention hypersensitivity/anaphylactic reactions and discontinuation if allergic reaction occurs, but do not specifically support rash/itching as described.
In rare cases, liver problems may develop with cefixime oral suspension.
Liver/hepatotoxicity warnings/sections were not provided in the supplied FDA label excerpts.
Other cephalosporins such as cefdinir or cefpodoxime may be considered as alternatives to cefixime oral suspension.
Comparative alternative selection was not provided in the supplied FDA label excerpts.
For certain infections, antibiotics from different classes such as macrolides might be prescribed as alternatives to cefixime oral suspension.
Alternative antibiotic class guidance was not provided in the supplied FDA label excerpts.
For certain infections, antibiotics from different classes such as fluoroquinolones might be prescribed as alternatives to cefixime oral suspension.
Alternative antibiotic class guidance was not provided in the supplied FDA label excerpts.
Cefixime original patents have long expired.
Patent/legal status is not addressed in the supplied FDA label excerpts.
Generic versions of cefixime... are widely available from various manufacturers.
Market availability/manufacturer distribution is not addressed in the supplied FDA label excerpts.
Contradictions
Low
AI Statement
Cefixime leads to bacterial death.
Label Reference
Not evaluable: provided FDA excerpts (5.1–5.5) do not address mechanism or bactericidal statement.
Important Omissions
Exact FDA-approved indication(s) and population limits/criteria for use (e.g., what infections cefixime is indicated for) were not provided, so indication-related claims cannot be verified.
Importance:
High
Dosage/administration details (dose, frequency, renal adjustment specifics, reconstitution instructions, shaking/storage/use-after-reconstitution period) were not provided in the supplied label excerpts.
Importance:
High
Contraindications, boxed warning text (if any), drug interactions, and adverse reaction listings were not provided in the supplied label excerpts.
Importance:
High
Monitoring recommendations (e.g., prothrombin time/vitamin K as applicable, dialysis monitoring) are present in supplied excerpts but were not mapped to any specific user claims; therefore omissions cannot be assessed relative to the requested audit scope.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims relate to dosing/administration (reconstitution, storage, use period, shaking) and adverse effects and alternative therapies, but the corresponding FDA label sections were not provided for verification. As a result, the alignment with FDA prescribing information cannot be established and unverified claims could mislead clinical use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Auditable
Primary Issue
Insufficient label coverage and missing/unclear claim-to-response mapping prevents a reliable label alignment audit.
Suggested Improvement
Provide (1) the exact AI-generated response text to be audited (not just a list of candidate statements), and (2) the full FDA label sections relevant to each category (Indications and Usage, Dosage and Administration including renal impairment and reconstitution/storage instructions, Contraindications, Warnings/Precautions including any liver-related warnings, Drug Interactions, Adverse Reactions, and Storage/Handling as applicable).